Biomarkers in dementia: clinical utility and new directions

First published: 2025-04-28

Last Edited: 2025-04-28

Number of edits: 1

Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.

Source:
Tags:

Backlinks

These are the other notes that link to this one.

Nothing links here, how did you reach this page then?

Comment

Share your thoughts on this note. Comments are not public, they are messages sent directly to my inbox.

Aquiles Carattino

This note you are reading is part of my digital garden. Follow the links to learn more, and remember that these notes evolve over time. After all, this website is not a blog.